According to industry estimates, the global respiratory syncytial virus (RSV) diagnostics market attained a value of USD 1,133.46 million in 2025. Driven by the rising incidence of RSV infections, particularly among infants, young children, and the elderly, along with increasing awareness of early and accurate diagnosis, the market is expected to witness strong growth over the forecast period. The industry is anticipated to expand at a CAGR of 10.20% during 2026–2035, reaching a valuation of USD 2,993.80 million by 2035.

RSV is a common respiratory virus that can cause severe lower respiratory tract infections, including bronchiolitis and pneumonia. Timely and accurate diagnosis is critical for effective patient management, infection control, and reducing the burden on healthcare systems. RSV diagnostics include molecular tests, antigen-based assays, and serological methods, which are widely used in hospitals, diagnostic laboratories, and point-of-care settings.

RSV Diagnostics Market Trends

A key trend shaping the global RSV diagnostics market is the increasing adoption of rapid and molecular diagnostic tests. Polymerase chain reaction (PCR)-based assays are gaining popularity due to their high sensitivity and specificity, enabling early detection of RSV infections. Additionally, the growing demand for point-of-care testing is driving the development of rapid diagnostic kits that deliver quick and reliable results, particularly in emergency and paediatric care settings.

Another notable trend is the integration of multiplex respiratory panels that can simultaneously detect RSV along with other respiratory pathogens such as influenza and SARS-CoV-2. These comprehensive diagnostic solutions improve clinical decision-making and operational efficiency, thereby supporting market growth.

Drivers of Growth

The primary driver of growth in the RSV diagnostics market is the increasing prevalence of RSV infections worldwide. Seasonal outbreaks and rising hospitalisation rates among vulnerable populations are significantly boosting the demand for diagnostic testing. Furthermore, heightened awareness among healthcare professionals and caregivers regarding the importance of early diagnosis is contributing to increased test utilisation.

Advancements in diagnostic technologies and increased healthcare expenditure are also supporting market expansion. Governments and healthcare organisations are investing in improved diagnostic infrastructure and surveillance programmes, particularly in developed economies, which is further driving the adoption of RSV diagnostic solutions.

Get a Free Sample Report with Table of Contents

Challenges and Opportunities

Despite favourable growth prospects, the market faces challenges such as limited access to advanced diagnostic technologies in low- and middle-income countries and the relatively high cost of molecular diagnostic tests. Additionally, variability in testing guidelines and reimbursement policies can impact market growth in certain regions.

However, these challenges present significant opportunities for market participants. The development of cost-effective, rapid, and easy-to-use diagnostic kits can enhance accessibility and adoption in resource-limited settings.